Bayer AG’s pharmaceuticals unit is on track for a return to growth as new drugs for cancer and kidney disease offset sales lost to patent expirations.
Bayer A.G. stock: contrarian Buy with €35 target. Click for this updated look at BAYZF stock prospects and why I am neutral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results